Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.ISR · Entity 694 | EVP of Sales & Marketing | October 22, 2020 | October 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date October 22, 2020 · Filed October 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,844 |
Reported balance
After 2020-10-22 transaction · row 1
1 source rowRow 1 · 2020-10-22 · Purchase · Acquired 28,844 · Balance 83,844 F1: Purchased pursuant to public offering that closed on October 22, 2020. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2025-10-22 | Direct | 689,422 |
Reported balance
After 2020-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-22 · Purchase · Acquired 14,422 · Balance 689,422 F2: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. |
| Common StockSEC Table I · non-derivative | IndirectThese shares are beneficially owned in an IRA for the benefit of the Reporting Person. | 50,000 |
Reported balance
Holding disclosure · report date 2020-10-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 50,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Purchased pursuant to public offering that closed on October 22, 2020.
F2: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2020 Filed Oct 28, 2020 20:45 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseWarrant (right to buy) · Derivative | 14,422 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-20-021859 · rdgdoc.xml · derivative · entry 3 Krachon Michael · CIK 0001677655 · EVP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,422 Underlying: Common Stock · 14,422 shares Expires 2025-10-22 F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:45 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 28,844 | $0.52 | $14,998.88 |
DisclosureSEC source: 0001437749-20-021859 · rdgdoc.xml · nonDerivative · entry 1 Krachon Michael · CIK 0001677655 · EVP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,844 F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020. F1 · price: Purchased pursuant to public offering that closed on October 22, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:48 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-20-013880 · rdgdoc.xml · derivative · entry 1 Krachon Michael · CIK 0001677655 · EVP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 150,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 21:30 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon stock | 50,000 | $0.39 | $19,495.00 |
DisclosureSEC source: 0001437749-19-023360 · rdgdoc.xml · nonDerivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Indirect · These shares are beneficially owned in an IRA for the benefit of the Reporting Person. Disclosed balance after: 50,000 Read SEC document |
| June 18, 2019 Filed Jun 24, 2019 20:58 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001437749-19-012559 · rdgdoc.xml · derivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 150,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested. Read SEC document |
| June 13, 2018 Filed Jun 20, 2018 20:14 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001437749-18-012130 · rdgdoc.xml · derivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: 25% vested as of 6/13/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/13/2019, until fully vested. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 3,900 | $0.48 | $1,872.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 15 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 100 | $0.48 | $48.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 14 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,100 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 200 | $0.47 | $94.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 13 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 200 | $0.48 | $96.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 12 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,800 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 40 | $0.49 | $19.60 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 11 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,600 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 300 | $0.47 | $141.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 10 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,560 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 10,160 | $0.50 | $5,080.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 9 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,260 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 200 | $0.46 | $92.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 8 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,100 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 500 | $0.47 | $235.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 7 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 126 | $0.47 | $59.22 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 6 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 1,400 | $0.50 | $700.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 5 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,274 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 700 | $0.50 | $350.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 4 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,874 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 10,600 | $0.50 | $5,300.00 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 3 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,174 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 6,965 | $0.50 | $3,482.50 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 2 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,574 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 21:07 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 19,609 | $0.50 | $9,804.50 |
DisclosureSEC source: 0001437749-17-019679 · rdgdoc.xml · nonDerivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,609 Read SEC document |
| June 27, 2017 Filed Jun 30, 2017 01:14 UTC Amendment | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642247-17-000017 · primary_doc.xml · derivative · entry 2 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-06-27 F1 · security: The two reported transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. F2 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:11 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642247-17-000010 · primary_doc.xml · derivative · entry 2 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-06-27 F1 · security: The two transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. F2 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested. Read SEC document |
| June 15, 2017 Filed Jun 30, 2017 01:14 UTC Amendment | Perspective Therapeutics, Inc. ISR · Entity 694 | Disposition to issuerStock Options (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001642247-17-000017 · primary_doc.xml · derivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-03-07 F1 · security: The two reported transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. F1 · derivative.exercise_date: The two reported transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 21:11 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | Disposition to issuerStock Options (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001642247-17-000010 · primary_doc.xml · derivative · entry 1 Krachon Michael · CIK 0001677655 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-03-07 F1 · security: The two transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. F1 · derivative.exercise_date: The two transactions involved a termination of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a new option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.